Pfizer reported higher-than-expected first-quarter sales and profit, boosting investor confidence. The company also pointed to a patent extension for its Vyndamax heart treatment and a favorable European court ruling tied to its COVID-19 vaccine. Together, the wins are expected to help secure stronger growth prospects after 2028.
Swipe through stories, personalise your feed, and save articles for later — all on the app.
